Skip to main content

In Brief This Week: Xifin, Theradiag, HTG Molecular, and More

NEW YORK (360Dx) – Xifin this week announced a partnership with Glidian to integrate that company's automated prior authorization capabilities with Xifin's revenue cycle management and laboratory information system solutions, Xifin RPM and Xifin LIS. Glidian offers an electronic platform that streamlines prior authorizations for healthcare providers. Xifin said the partnership will enable diagnostic service providers to increase revenue by reducing prior authorization-related denials. It also builds on the prior authorization workflow, logic, and document storage available within Xifin RPM, Xifin said.


IVD and theranostic firm Theradiag this week reported a 2 percent year-over-year drop in total revenues for full-year 2018. For the year, the company reported revenues of €8.9 million ($10.1 million) compared to €9.1 million in 2017. Theranostics-based revenues were down about 4 percent year over year to €4.0 million from €4.2 million, while Lisa Tracker kits revenues grew 17 percent to €3.9 million from €3.3 million. IVD revenues were steady at €4.9 million. Theradiag exited 2018 with €3.4 million in cash.


HTG Molecular announced this week that it has amended its second precision diagnostic partnership program with Qiagen. According to the firm, the amendment extends the use of the investigational-use-only assay the partners previously developed as part of the program. HTG expects the amendment to generate revenue in the low single-digit millions for the additional activities.


Indian diagnostic lab network Lucid Diagnostics said this week that it will offer Mapmygenome's DNA Onco Screen test to consumers and physicians for the prevention and early detection of cancer. DNA Onco Screen assesses genetic predisposition to various cancers, physiological traits known to trigger cancer, and lifestyle traits linked to cancer risk. The assay also identifies key clinical markers associated with cancer. Patients receiving the test also have access to genetic counseling.


Abbott's board of directors announced a quarterly dividend of $.32 per share, payable on May 15 to shareholders of record on April 15.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.